paradoxical |
440 |
psoriasis |
440 |
rheumatoid arthritis |
440, 416, 426 |
tofacitinib |
440, 343 |
neuropathic pain |
409 |
psoriatic arthritis |
409 |
magnetic resonance imaging |
443 |
neuropsychiatric systemic lupus erythematosus |
443 |
vasculitis |
443 |
antiphospholipid antibodies |
449 |
granulomatosis with polyangiitis |
449 |
pyoderma gangrenosum |
449 |
rituximab |
449 |
bilirubin |
351 |
disease activity |
351, 416 |
primary sjögren's syndrome |
351 |
dynamic contrast-enhanced magnetic resonance imaging |
416 |
vascular endothelial growth factor |
416 |
guideline |
309 |
hand |
309 |
management |
309 |
osteoarthritis |
309 |
treatment |
309 |
behçet’s disease |
401 |
fibromyalgia |
401 |
genital ulcer |
401 |
children |
357 |
corticosteroid |
357 |
damage |
357 |
growth |
357 |
juvenile systemic lupus erythematosus |
357 |
collagen |
343 |
fibroblast cell culture |
343 |
janus kinase/signal transducers and activators of the transcription |
343 |
25-hydroxyvitamin d |
335 |
carotid intima |
335 |
high-density lipoproteins |
335 |
thickness |
335 |
triglycerides |
335 |
capillaroscopy |
321 |
systemic sclerosis |
321 |
99mtc-pertechnetate scintigraphy |
321 |
biological disease-modifying anti-rheumatic drugs |
376 |
conventional disease-modifying anti-rheumatic drugs |
376 |
demodex folliculorum |
376 |
infestation |
376 |
mite |
376 |
rheuma- toid arthritis |
376 |
reliability |
385 |
shoulder impingement syndrome |
385 |
ultrasound |
385 |
platelet distribution width |
394 |
predictor |
394 |
pulmonary arterial hypertension |
394 |
systemic lupus erythematosus |
394 |
beta-2 adrenergic receptor |
328 |
fibromyalgia syndrome |
328 |
polymorphism |
328 |
ankylosing spondylitis |
435 |
arterial stiffness |
435 |
cardiovascular disease |
435 |
pulse wave velocity |
435 |
interstitial |
366 |
korea |
366 |
lung diseases |
366 |
mycophenolic acid |
366 |
scleroderma |
366 |
systemic |
366 |
joints |
426 |
risk factors |
426 |
surgery |
426 |
tunisian |
426 |